Corton Capital’s Kalaris Therapeutics KLRS Stock Holding History

Corton Capital’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-456	Closed	-$41K	–	385
2022 Q2	$41K	Buy	+456	New	+$47.8K	0.04%	317

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corton Capital's KLRS Position: Q3 2022 in Review

Corton Capital sold out of Kalaris Therapeutics (KLRS) in Q3 2022, closing a stake of 456 shares — an estimated $41K sold.

Corton Capital first reported a position in KLRS in Q2 2022 and held it in 1 quarter. The position peaked at $41K in Q2 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q3 2022.

Corton Capital reported no remaining Kalaris Therapeutics position as of Q3 2022 after selling out during the quarter.
Corton Capital sold 456 Kalaris Therapeutics shares in Q3 2022, an estimated $41K.
Corton Capital first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 1 quarter.
Corton Capital's Kalaris Therapeutics position peaked at $41K in Q2 2022.
85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2022.

Based on Corton Capital's 13F filing for Q3 2022, filed 14 Nov 2022.